11 July 2018

Ellex Secures TGA Approval for new STAAR Lens, Continues Partnership

Adelaide, Australia XX June 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it will continue its exclusive distribution agreement with US-based STAAR Surgical Company (STAAR) to market and distribute the STAAR portfolio of industry-leading refractive and cataract lens implants in Australia.

This coincides with Ellex’s successful registration of the EVO+ Visian ICL™ refractive lens with the Therapeutic Goods Administration (TGA) in Australia.

Ellex first entered into partnership with STAAR in 2011, leveraging its distribution channel and existing sales and marketing infrastructure to promote the STAAR range of refractive (ICL and TICL) lenses and cataract (IOL) lenses.

“There are many synergies between STAAR and Ellex. STAAR lenses are a perfect fit for our diagnostic and treatment technologies,” said Mr. Spurling.

“STAAR continues to represent an important avenue through which to grow our business, and to address the growing and diverse technology needs of our Australian customers.”

During the 2019 financial year Ellex will invest in growth of the STAAR business through a number of initiatives, including the appointment of a dedicated clinical specialist and up-skilling of its national sales team.

“This will increase the scope of service and support provided across the EVO Visian ICL portfolios, including the recently approved EVO+ Visian ICL”, commented Mr. Spurling.

 

EVO and EVO+ Visian, Refractive Lens

The EVO Visian ICL™ (Implantable Collamer Lens) and EVO+ Visian ICTL™ are custom lenses designed for the treatment of refractive error, including myopia (near-sightedness) and hyperopia (far-sightedness). Together, these refractive disorders affect a large proportion of the population and have traditionally been treated with invasive LASIK or PRK surgery.

“The EVO Visian ICL has transformed vision correction. Not only can it be used for a wider treatment range of myopia than traditional LASIK and PRK procedures, it is also minimally invasive. More than 800,000 EVO Visian ICL lenses have been implanted worldwide and, with the introduction of the new EVO+ Visian ICL, combined with increased patient education of the benefits of ICL technology, we expect the uptake of this technology to grow considerably in Australia over the coming years,” commented Mr. Spurling.

The EVO+ Visian ICL offers an expanded optic (-0.5 D to -14.0 D) and is designed for patients with larger pupils.

“EVO Visian ICL and EVO+ Visian ICL complement our breakthrough, proprietary LFT Laser Floater Treatment technology, aimed at improving the functional vision of symptomatic patients suffering from floaters.”

 

TORIC, Cataract Lens

An advanced foldable lens, the Toric™ IOL (intraocular lens) is implanted into the patient’s eye during cataract surgery. It was one of the first lenses available for the treatment both of cataract and astigmatism. Astigmatism is estimated to affect up to 20% of patients who undergo cataract surgery.

“With the Toric IOL, ophthalmologists can simultaneously treat the cataract and the astigmatism – offering a unique advantage over existing IOL technologies. It also ties in perfectly with Ellex’s suite of high precision YAG lasers for capsulotomy, which help to maintain the integrity of the lens during the treatment of secondary cataract.”


ABOUT STAAR

STAAR Surgical Company (Nasdaq: STAA) is a leading developer, manufacturer and marketer of implantable lenses for use in ophthalmic surgery. Founded in 1982, STAAR has evolved into a global surgical eye correction technology leader. Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA.


ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Fremont, Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com


For further information on Ellex please contact:

Tom Spurling, CEO

Ellex Medical Lasers Limited

3 Second Avenue, Mawson Lakes, SA, 5095

W +61 8 7074 8293 | M +61 417 818 658

tspurling@ellex.com

Mark Lindh, Investor Relations & Corporate

W +61 8 87074 8200 | M +61 414 551 361

mlindh@ellex.com

 

 

Maria Maieli, CFO & Company Secretary

Ellex Medical Lasers Limited

3 Second Avenue, Mawson Lakes, SA, 5095

W +61 8 7074 8200

mmaieli@ellex.com